603538.SS SHH
Ningbo Menovo Pharmaceutical Co., Ltd.
1W: -0.8%
1M: +8.1%
3M: +2.1%
YTD: +33.6%
1Y: +9.7%
3Y: +55.8%
5Y: -7.1%
¥28.59 ($4.26)
+2.60 (+10.00%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$98M
+968.0% ▲
5Y CAGR: -11.5%
Capital Expenditures
$179M
+18.3% ▲
5Y CAGR: -11.4%
Free Cash Flow
-$82M
+61.1% ▲
Dividends Paid
$23M
+61.7% ▲
Buybacks
$630K
+43.6% ▲
Net Change in Cash
$39M
+114.8% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $173M | $158M | $368M | $12M | $67M |
| Depreciation & Amort. | $85M | $99M | $102M | $118M | $134M |
| Stock-Based Comp. | $11M | $5M | $25M | $0 | $0 |
| Change in Working Capital | -$3M | -$62M | -$85M | -$208M | -$185M |
| Other Non-Cash Items | -$33M | $42M | -$91M | $96M | $82M |
| Operating Cash Flow | $252M | $221M | $277M | $9M | $98M |
| — Investing Activities — | |||||
| Capital Expenditures | -$312M | -$530M | -$572M | -$220M | -$179M |
| Acquisitions (Net) | $484K | -$47M | $488M | $106M | $0 |
| Investment Purchases | -$865M | -$1.6B | -$714M | -$1.2B | -$468M |
| Investment Sales | $694M | $1.6B | $902M | $975M | $545M |
| Other Investing | $4M | $52M | -$55M | $13M | $2M |
| Investing Cash Flow | -$479M | -$603M | $50M | -$324M | -$100M |
| — Financing Activities — | |||||
| Net Debt Issuance | $194M | $10M | $19M | $92M | $12M |
| Stock Repurchased | -$531K | -$171K | -$97K | -$1M | -$630K |
| Dividends Paid | -$16M | -$14M | -$30M | -$59M | -$23M |
| Other Financing | $14M | $587M | -$148M | $22M | $44M |
| Financing Cash Flow | $138M | $583M | -$178M | $55M | $32M |
| Net Change in Cash | -$91M | $198M | $163M | -$263M | $39M |
| Cash End of Period | $175M | $374M | $537M | $274M | $313M |
| Free Cash Flow | -$60M | -$309M | -$295M | -$210M | -$82M |